Skip navigation
Covered by Medicare for patients with stage II-IV and oligometastatic colorectal cancer

Signatera™ for Colorectal Cancer

Knowing Earlier Can Make A Difference

Signatera™ is custom-built to your unique set of tumor mutations to predict colorectal cancer recurrence. Because it is highly sensitive it can detect very small traces of tumor in your body so you can know earlier if cancer is present and make more informed decisions regarding your treatment.

Pro golfer Charlie Rymer uses Signatera™ to inform his treatment.

Hear how Beth was able to get back to living after her stage III CRC treatment

Bespoke CRC
Bespoke CRC

Discover our BESPOKE study of ctDNA-guided therapy for colorectal cancer

Do you want to be a part of something extraordinary? Join Natera’s BESPOKE CRC study to make a difference for individuals who, like you, have been diagnosed with colorectal cancer (CRC). The study will examine the use of Signatera™ and the impact it has on treatment decisions for clinical outcomes in patients with stage II and III colorectal cancer. The study will enroll at least one thousand patients. Natera and its collaborators will collect data on clinical decisions, benefits, and outcomes from enrolled patients for two years. Participants may receive up to $150 dollars for their time.


Visit our Signatera™ BESPOKE study page to learn more about participating in the clinical study.

How is the Signatera™ test performed?


Personalized, tumor-informed assay

One-time, primary tissue sample and matched normal tissue is required for whole exome sequencing and personalized test design.


Ultrasensitive ctDNA detection

Signatera™ is designed to detect ctDNA of somatic and truncal variants to optimize sensitivity. Tumor-informed method enables filtering of CHIP mutations to decrease false positive rates.


Optimized for longitudinal monitoring

Once the patient’s personalized test has been designed, only a blood sample is needed each subsequent time Signatera™ is ordered for the program or Surveillance program.

Peace of mind powered by Signatera™

Helping Patients Make Informed Decisions

For patients undergoing treatment for colon cancer, each scan can be a scary experience. Wondering if the treatments are working and the nagging fear of colorectal cancer recurrence can cause a great deal of anxiety and worry.

Signatera™ can help alleviate these concerns by making it much easier for doctors to assess response to treatment and watch for the earliest warning signs of recurrence. It is designed to detect molecular residual disease by looking for the distinct tumor DNA in each patient. This personalized, tumor-informed assay is optimized to provide accurate detection for each individual, making it a powerful source of information to help guide future care decisions.

Access Personalized Testing

Medicare Coverage

  • Signatera™ is covered by Medicare for patients with stage II-IV and oligometastatic colorectal cancer.
  • We welcome all insurance plans. Please refer to our list of in-network plans that we participate with, or call your insurance provider.
  • We offer financial assistance programs for those that qualify.

More Information

  • Find answers to your questions about eligibility, results, ordering, and more
  • Don’t see your question? Contact us here.

Check out our FAQ page to learn more about Signatera™

Is Signatera™ right for you?

We’re here to help you find out

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time.

icon-angle icon-bars icon-times